Conformational states and recognition of amyloidogenic peptides of human insulin-degrading enzyme

Insulin-degrading enzyme (IDE) selectively degrades the monomer of amyloidogenic peptides and contributes to clearance of amyloid β (Aβ). Thus, IDE retards the progression of Alzheimer’s disease. IDE possesses an enclosed catalytic chamber that engulfs and degrades its peptide substrates; however, the molecular mechanism of IDE function, including substrate access to the chamber and recognition, remains elusive. Here, we captured a unique IDE conformation by using a synthetic antibody fragment as a crystallization chaperone. An unexpected displacement of a door subdomain creates an ∼18-Å opening to the chamber. This swinging-door mechanism permits the entry of short peptides into the catalytic chamber and disrupts the catalytic site within IDE door subdomain. Given the propensity of amyloidogenic peptides to convert into β-strands for their polymerization into amyloid fibrils, they also use such β-strands to stabilize the disrupted catalytic site resided at IDE door subdomain for their degradation by IDE. Thus, action of the swinging door allows IDE to recognize amyloidogenicity by substrate-induced stabilization of the IDE catalytic cleft. Small angle X-ray scattering (SAXS) analysis revealed that IDE exists as a mixture of closed and open states. These open states, which are distinct from the swinging door state, permit entry of larger substrates (e.g., Aβ, insulin) to the chamber and are preferred in solution. Mutational studies confirmed the critical roles of the door subdomain and hinge loop joining the N- and C-terminal halves of IDE for catalysis. Together, our data provide insights into the conformational changes of IDE that govern the selective destruction of amyloidogenic peptides.

[1]  D. Svergun,et al.  Mathematical methods in small-angle scattering data analysis , 1991 .

[2]  R L Stanfield,et al.  Antibody-antigen interactions: new structures and new conformational changes. , 1994, Current opinion in structural biology.

[3]  D. Svergun,et al.  CRYSOL : a program to evaluate X-ray solution scattering of biological macromolecules from atomic coordinates , 1995 .

[4]  J Deisenhofer,et al.  Crystal structure of the cytochrome bc1 complex from bovine heart mitochondria. , 1997, Science.

[5]  D. Goldberg,et al.  Identification and Characterization of Falcilysin, a Metallopeptidase Involved in Hemoglobin Catabolism within the Malaria Parasite Plasmodium falciparum* , 1999, The Journal of Biological Chemistry.

[6]  I. Kurochkin Insulin-degrading enzyme: embarking on amyloid destruction. , 2001, Trends in biochemical sciences.

[7]  J. Deisenhofer,et al.  Crystal structures of mitochondrial processing peptidase reveal the mode for specific cleavage of import signal sequences. , 2001, Structure.

[8]  Dmitri I. Svergun,et al.  PRIMUS: a Windows PC-based system for small-angle scattering data analysis , 2003 .

[9]  C. Dobson,et al.  Protein misfolding, functional amyloid, and human disease. , 2006, Annual review of biochemistry.

[10]  Kenneth A. Johnson,et al.  The closed structure of presequence protease PreP forms a unique 10 000 Å3 chamber for proteolysis , 2006 .

[11]  Kenneth A. Johnson,et al.  The closed structure of presequence protease PreP forms a unique 10,000 Angstroms3 chamber for proteolysis. , 2006, The EMBO journal.

[12]  Wei-Jen Tang,et al.  The C-terminal domain of human insulin degrading enzyme is required for dimerization and substrate recognition. , 2006, Biochemical and biophysical research communications.

[13]  A. Joachimiak,et al.  Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism , 2006, Nature.

[14]  D. Kern,et al.  Dynamic personalities of proteins , 2007, Nature.

[15]  T. Hudson,et al.  A genome-wide association study identifies novel risk loci for type 2 diabetes , 2007, Nature.

[16]  D. Blacker,et al.  Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database , 2007, Nature Genetics.

[17]  Wei-Jen Tang,et al.  Structure of Substrate-free Human Insulin-degrading Enzyme (IDE) and Biophysical Analysis of ATP-induced Conformational Switch of IDE* , 2007, Journal of Biological Chemistry.

[18]  E. Malito,et al.  Amyloid β-degrading cryptidases: insulin degrading enzyme, presequence peptidase, and neprilysin , 2008, Cellular and Molecular Life Sciences.

[19]  Wei-Jen Tang,et al.  Molecular bases for the recognition of short peptide substrates and cysteine-directed modifications of human insulin-degrading enzyme. , 2008, Biochemistry.

[20]  S. Koide Engineering of recombinant crystallization chaperones. , 2009, Current opinion in structural biology.

[21]  S. Uysal Application of synthetic antibodies to structural biology: Crystal structures of the closed and the open conformation of full-length KcsA , 2009 .

[22]  R. Morimoto,et al.  Biological and chemical approaches to diseases of proteostasis deficiency. , 2009, Annual review of biochemistry.

[23]  Wei-Jen Tang,et al.  Molecular Basis of Catalytic Chamber-assisted Unfolding and Cleavage of Human Insulin by Human Insulin-degrading Enzyme* , 2009, Journal of Biological Chemistry.

[24]  K. Nagata,et al.  Crystal structure of TTHA1264, a putative M16‐family zinc peptidase from Thermus thermophilus HB8 that is homologous to the β subunit of mitochondrial processing peptidase , 2009, Proteins.

[25]  Wei-Jen Tang,et al.  Structural changes in intermediate filament networks alter the activity of insulin‐degrading enzyme , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  Greg L. Hura,et al.  Crystal and solution structures of a prokaryotic M16B peptidase: an open and shut case. , 2009, Structure.

[27]  B. Strooper Proteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process , 2010 .

[28]  R. Koenen,et al.  Polymerization of MIP‐1 chemokine (CCL3 and CCL4) and clearance of MIP‐1 by insulin‐degrading enzyme , 2010, The EMBO journal.

[29]  Wei-Jen Tang,et al.  Molecular basis for the recognition and cleavages of IGF-II, TGF-alpha, and amylin by human insulin-degrading enzyme. , 2010, Journal of molecular biology.

[30]  T. Funke,et al.  Insulin-degrading Enzyme Modulates the Natriuretic Peptide-mediated Signaling Response* , 2010, The Journal of Biological Chemistry.

[31]  L. Hersh,et al.  Mixed Dimers of Insulin-degrading Enzyme Reveal a Cis Activation Mechanism* , 2011, The Journal of Biological Chemistry.

[32]  B. Mikami,et al.  Heterosubunit composition and crystal structures of a novel bacterial M16B metallopeptidase. , 2011, Journal of molecular biology.

[33]  D. Bartel,et al.  A portable RNA sequence whose recognition by a synthetic antibody facilitates structural determination , 2010, Nature Structural &Molecular Biology.

[34]  L. Hersh,et al.  Anion Activation Site of Insulin-degrading Enzyme* , 2011, The Journal of Biological Chemistry.

[35]  A. Saghatelian,et al.  Peptidomics approach to elucidate the proteolytic regulation of bioactive peptides , 2012, Proceedings of the National Academy of Sciences.

[36]  A. Koide,et al.  Identification of a tetratricopeptide repeat-like domain in the nicastrin subunit of γ-secretase using synthetic antibodies , 2012, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Shohei Koide,et al.  Teaching an old scaffold new tricks: monobodies constructed using alternative surfaces of the FN3 scaffold. , 2012, Journal of molecular biology.

[38]  A. Koide,et al.  T Cell Receptor-Like Recognition of Tumor In Vivo by Synthetic Antibody Fragment , 2012, PloS one.